Loading
Regeneron Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 14 Jan 2016.
Regeneron Pharmaceuticals, Inc.: what insiders have been doing
Regeneron Pharmaceuticals, Inc., founded in 1988, is a Healthcare & Pharma company based in Eastview, United States. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 18 October 2026, 89 filings were filed, from 24 insiders.
Only sales appear on the open market, 43 sales in all totalling €5.3M, filed by 5 insiders. McCourt Marion filed the largest sale, €892k, on 3 September 2026, which represents 0.0013% of the company's market value.
Compared with its exchange (5,810 companies, median 19 filings), a count of 89 filings is above the norm. The full history, which starts in 2016, counts 18 purchases against 136 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 14.34 bn USD and net income at 4.50 bn USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
476
Thresholds
n/a
Buy Volume
n/a
18 ops. · all time
Sell Volume
€241M
136 ops. · all time
Who traded when
BuySaleAndrew J. Murphy27 sales
Arthur F. Ryan12 sales
Kathryn Guarini2 sales
Marion McCourt2 sales
Huda Y. Zoghbi1 sale
Jason Pitofsky1 sale
Analyst consensus: bullish or bearish?
Analysts rate Regeneron Pharmaceuticals, Inc. Buy (bullish), based on 26 analysts. Average price target: US$859.69.
Fundamental score
Ranked 3,366 of 24,161 companies
70.7
score / 100
Value56
Quality85
FCF yld4.6%
Earn yld5.5%
EV/EBITDA14.5x
ROE14%
Gross mgn85%
Net mgn31%
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$778.36
Analyst consensus
26 analystsBuy
US$730.00Target US$859.69(+10%)US$1,030.00
Income statement
RevenueUS$14.3B
Gross profitUS$12.2B85% margin
EBITDAUS$5.8B41% margin
Net incomeUS$4.5B27.9% margin
Valuation
PER (trailing)18.6x
PER (forward)12.6x
P/Book2.5x
Beta0.15
Balance sheet & cash
Market capUS$80.1B
Total debtUS$2.7B
Free Cash FlowUS$3.8B
Debt / Equity9%
Profitability & ownership
ROE14.0%
ROA6.5%
% insiders2.1%
% institutions93.6%
Last declaration on 15 October 2026
Declarations476 total
17,000 shares@ US$381.92Common StockSEC:0001796226-26-000002:0
12,853 shares@ US$754.58Common StockSEC:0001796226-26-000002:1
6 shares@ US$753.76Common StockSEC:0001796226-26-000002:2
35 shares@ US$755.91Common StockSEC:0001796226-26-000002:3
16 shares@ US$757.68Common StockSEC:0001796226-26-000002:4
24 shares@ US$758.16Common StockSEC:0001796226-26-000002:5
14 shares@ US$759.96Common StockSEC:0001796226-26-000002:6
74 shares@ US$760.65Common StockSEC:0001796226-26-000002:7
27 shares@ US$761.36Common StockSEC:0001796226-26-000002:8
55 shares@ US$762.57Common StockSEC:0001796226-26-000002:9
25 shares@ US$763.76Common StockSEC:0001796226-26-000002:10
219 shares@ US$764.40Common StockSEC:0001796226-26-000002:11
271 shares@ US$765.39Common StockSEC:0001796226-26-000002:12
279 shares@ US$766.47Common StockSEC:0001796226-26-000002:13
192 shares@ US$767.39Common StockSEC:0001796226-26-000002:14
105 shares@ US$768.33Common StockSEC:0001796226-26-000002:15
127 shares@ US$769.30Common StockSEC:0001796226-26-000002:16
12 shares@ US$770.20Common StockSEC:0001796226-26-000002:17
283 shares@ US$771.56Common StockSEC:0001796226-26-000002:18
211 shares@ US$772.56Common StockSEC:0001796226-26-000002:19
224 shares@ US$773.40Common StockSEC:0001796226-26-000002:20
121 shares@ US$774.48Common StockSEC:0001796226-26-000002:21
376 shares@ US$775.46Common StockSEC:0001796226-26-000002:22
66 shares@ US$776.31Common StockSEC:0001796226-26-000002:23
38 shares@ US$777.76Common StockSEC:0001796226-26-000002:24
25 of 476 declarations
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker REGN. Headquartered in Tarrytown, New York, in the United States, the company was founded in 1988 and has built a reputation as one of the most scientifically driven large-cap biotechnology companies. Its business model is highly integrated, spanning discovery, development, and commercialization, with a strong internal research culture and proprietary platforms such as VelociSuite® and the Regeneron Genetics Center®. ([regeneron.com](https://www.regeneron.com/about/our-company?utm_source=openai))
Regeneron develops and commercializes medicines across several therapeutic areas, including eye diseases, allergic and inflammatory disorders, oncology, cardiovascular and metabolic diseases, rare diseases, infectious diseases, and selected neurological conditions. Its best-known products include Dupixent® (co-marketed with Sanofi), EYLEA® and EYLEA HD® for retinal diseases, Libtayo® in oncology, and additional products such as Praluent®, Kevzara®, Evkeeza®, Inmazeb®, and Veopoz®. Despite this broader portfolio, the company’s earnings profile remains anchored by a few major franchises, especially Dupixent and the EYLEA/EYLEA HD ophthalmology franchise, which are central to its growth and profitability profile. ([regeneron.com](https://www.regeneron.com/about/our-company?utm_source=openai))
Read moreShow less
From a competitive standpoint, Regeneron is widely regarded as a leading biotech because of its ability to convert scientific discovery into approved medicines at scale. The company stands out for its expertise in antibody engineering, protein biology, and genetic medicine, allowing it to maintain a deep pipeline with many programs originating in-house. In 2025 and early 2026, Regeneron continued to expand both its commercial portfolio and clinical pipeline, with regulatory approvals and late-stage progress across immunology, ophthalmology, oncology, and rare diseases. ([regeneron.com](https://www.regeneron.com/about/our-company?utm_source=openai))
Recent highlights include the FDA’s April 2026 approval of EYLEA HD with dosing intervals of up to 20 weeks in certain retinal indications, multiple new Dupixent approvals in 2025-2026, and the accelerated approval of Otarmeni™, Regeneron’s first genetic medicine and first gene therapy in a rare hearing-loss indication. The company also announced a radiopharmaceutical collaboration with Telix and a U.S. government agreement related to pricing for certain medicines, while reiterating its commitment to substantial domestic R&D and manufacturing investment. For international investors, Regeneron remains a high-quality growth name in Health & Pharma, combining a proprietary science platform, a deep pipeline, and leading commercial franchises on the U.S. NASDAQ market. ([investor.regeneron.com](https://investor.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-approved-fda-first-and-only-injectable/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
